Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANIX Anixa Biosciences

Not Yet Opened 12-18 16:00:00 EST

3.24

-0.02

-0.77%

盘后3.34

+0.10+3.17%

19:17 EST

High3.41	Low3.20	Vol354.62K
Open3.31	D1 Closing3.27	Amplitude6.43%
Mkt Cap106.65M	Tradable Cap98.70M	Total Shares32.92M
T/O1.16M	T/O Rate1.16%	Tradable Shares30.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANIX","market":"US","secType":"STK","nameCN":"Anixa Biosciences","latestPrice":3.24,"timestamp":1766091600000,"preClose":3.265,"halted":0,"volume":354616,"hourTrading":{"tag":"盘后","latestPrice":3.3428,"preClose":3.24,"latestTime":"19:17 EST","volume":527,"amount":1752.05,"timestamp":1766103437877},"delay":0,"floatShares":30462667,"shares":32916915,"eps":-0.344493,"marketStatus":"Not Yet Opened","change":-0.025,"latestTime":"12-18 16:00:00 EST","open":3.31,"high":3.41,"low":3.2,"amount":1160865.4055903999,"amplitude":0.064319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.344493,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.265,"preHourTrading":{"tag":"盘前","latestPrice":3.3001,"preClose":3.265,"latestTime":"09:26 EST","volume":2979,"amount":9898.6366908,"timestamp":1766067974100},"postHourTrading":{"tag":"盘后","latestPrice":3.3428,"preClose":3.24,"latestTime":"19:17 EST","volume":527,"amount":1752.05,"timestamp":1766103437877},"volumeRatio":0.270955,"impliedVol":1.7452,"impliedVolPercentile":0.78},"requestUrl":"/m/hq/s/ANIX","defaultTab":"news","newsList":[{"id":"2591641797","title":"Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641797","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641797?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:45","pubTimestamp":1765806324,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. has announced the completion of the transfer of the Investigational New Drug application  for its breast cancer vaccine from Cleveland Clinic, making Anixa the sponsor for future development and clinical trials. The company reported that enrollment for the Phase 1 clinical trial of the vaccine is complete, with encouraging immune response and safety data observed. Results from the Phase 1 trial were presented at the San Antonio Breast Cancer Symposium on December 11. Anixa plans to advance the vaccine into a Phase 2 clinical trial, utilizing multiple clinical sites, including Cleveland Clinic. The vaccine targets α-lactalbumin, a protein expressed in many forms of breast cancer, and is being developed in collaboration with Cleveland Clinic.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1Tjnqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2591641246","title":"Anixa Biosciences Announces Transfer of Ind for Breast Cancer Vaccine From Cleveland Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641246?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:45","pubTimestamp":1765806300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA23HHXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2590502472","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:41 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502472","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590502472?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:41","pubTimestamp":1765550487,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:41 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAQN2LDDGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2590506676","title":"Anixa Biosciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590506676?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:33","pubTimestamp":1765542780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 07:33 ET (12:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX"],"gpt_icon":0},{"id":"2590542270","title":"Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2590542270","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590542270?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:02","pubTimestamp":1765494140,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. announced the final results of its Phase 1 clinical trial for an investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense, met all major primary endpoints. The vaccine was found to be safe and well tolerated at the maximum tolerated dose, with immune responses observed in 74% of participants. In combination with Keytruda, the vaccine generated T cell responses without major additional side effects. The results support the advancement of the program to Phase 2 development, with plans for a neoadjuvant combination study in newly diagnosed breast cancer patients. The final data have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8JDq3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2590542278","title":"Anixa Biosciences Inc - Vaccine Safe and Well Tolerated at Maximum Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2590542278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590542278?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:02","pubTimestamp":1765494122,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA4XRMWV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2590054222","title":"Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590054222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590054222?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:02","pubTimestamp":1765494122,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA4XRMWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2590093580","title":"Anixa Biosciences CEO to Join Water Tower Research Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2590093580","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590093580?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:00","pubTimestamp":1765375253,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. will participate in the Water Tower Research Fireside Chat on Monday, December 15, 2025, at 1:00pm ET. The event will feature Anixa's Chairman and CEO, Dr. Amit Kumar, discussing topics such as final data from the company's Phase 1 breast cancer vaccine trial, implications of the retired protein strategy for cancer vaccines, and next steps for vaccine development. The session is open to all investors, who can register through Water Tower Research.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLbCXhPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2584741625","title":"Anixa Biosciences Secures WHO Approval for CAR-T Therapy Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2584741625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584741625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:15","pubTimestamp":1763385322,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. announced that the World Health Organization  has approved the International Nonproprietary Name  \"liraltagene autoleucel\" for its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The assignment of this unique, globally recognized name marks a key milestone toward the potential future commercialization of the therapy. The INN approval ensures clear identification and safe prescription of the treatment as Anixa continues its ongoing Phase 1 clinical trial in partnership with Moffitt Cancer Center. No grant or funding announcement involving multiple organizations was included.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8DXZ1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2584625762","title":"Anixa Biosciences Announces World Health Organization (Who) Approval of International Non-Proprietary Name for Its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625762?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:15","pubTimestamp":1763385300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA8LKF9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2582980817","title":"Anixa Biosciences CEO to Join Water Tower Research Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2582980817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582980817?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:30","pubTimestamp":1762788618,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. will participate in the Water Tower Research Fireside Chat Series on Tuesday, November 11, 2025. The company will present an overview of its clinical programs and provide an update on the status of its breast cancer vaccine Phase 1 clinical trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL14jwzx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2581988286","title":"Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988286?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:30","pubTimestamp":1762529427,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Doximity (DOCS – Research Report), Cartesian Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-doximity-docs-cartesian-therapeutics-rnac-and-anixa-biosciences-anix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-doximity-docs-cartesian-therapeutics-rnac-and-anixa-biosciences-anix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LU0128526141.USD","BK4581","BK4613","DOCS","HCSG","LU0029874061.USD","ANIX","RNAC","LABU","BK4167","XLV","BK4137","BK4551","BK4139","BK4585","BK4588","XBI"],"gpt_icon":0},{"id":"2581773574","title":"BRIEF-Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773574","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581773574?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:57","pubTimestamp":1762351065,"startTime":"0","endTime":"0","summary":"BRIEF-Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland ClinicNov 5 (Reuters) - Anixa Biosciences Inc ANIX.O:ANIXA BIOSCIENCES ANNOUNCES EXECUTION OF DATA TRANSFER AGREEM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA6QGYY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2581773325","title":"Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773325","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581773325?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:55","pubTimestamp":1762350923,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug  sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL25rKLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2577304004","title":"Anixa Biosciences to Present at Spartan Capital Securities Second Annual Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577304004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577304004?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:46","pubTimestamp":1761223566,"startTime":"0","endTime":"0","summary":"Anixa Biosciences Inc., a biotechnology company focused on the treatment and prevention of cancer, will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. President and CFO Mike Catelani will deliver a presentation and be available for one-on-one meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on October 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL73vBLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2576851160","title":"Anixa Biosciences Secures Chinese Patent for Breast Cancer Vaccine Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851160?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:26","pubTimestamp":1760963160,"startTime":"0","endTime":"0","summary":"Anixa Biosciences announced that the Chinese National Intellectual Property Administration has issued a patent covering key aspects of its breast cancer vaccine technology. The newly granted patent extends intellectual property protection for the vaccine in China into the 2040s, supporting Anixa's global development and commercialization plans. The vaccine, developed in collaboration with Cleveland Clinic, targets the human α-lactalbumin protein to help prevent and treat certain types of breast cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on October 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL4yT8YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2576954851","title":"Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2576954851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576954851?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:25","pubTimestamp":1760963100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUA97FHYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2573908922","title":"Anixa Biosciences Completes Phase 1 Breast Cancer Vaccine Trial and Plans Results Presentation in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573908922","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573908922?lang=en_us&edition=fundamental","pubTime":"2025-10-08 23:00","pubTimestamp":1759935623,"startTime":"0","endTime":"0","summary":"Anixa Biosciences, Inc.  has completed the final patient visit in its Phase 1 clinical trial evaluating a novel breast cancer vaccine, which was invented at Cleveland Clinic. The trial enrolled a total of 35 women across three cohorts: 26 patients with triple-negative breast cancer at risk of recurrence, four women in a prevention group with genetic mutations who opted for preventive mastectomy, and five patients who received the vaccine in combination with pembrolizumab. According to company statements, full clinical results will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025, following the submission of final study reports to the U.S. Department of Defense and the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL85l8bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2573966256","title":"Anixa Biosciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2573966256","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573966256?lang=en_us&edition=fundamental","pubTime":"2025-10-07 23:02","pubTimestamp":1759849320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 11:02 ET (15:02 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX"],"gpt_icon":0},{"id":"2573791957","title":"Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2573791957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573791957?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:31","pubTimestamp":1759840270,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA5HGWB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anixa.com","stockEarnings":[{"period":"1week","weight":-0.325},{"period":"1month","weight":-0.2098},{"period":"3month","weight":-0.0182},{"period":"6month","weight":-0.0414},{"period":"1year","weight":0.2806},{"period":"ytd","weight":0.3966}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.159061},{"month":2,"riseRate":0.3,"avgChangeRate":-0.059165},{"month":3,"riseRate":0.2,"avgChangeRate":-0.066814},{"month":4,"riseRate":0.3,"avgChangeRate":-0.022759},{"month":5,"riseRate":0.4,"avgChangeRate":-0.086037},{"month":6,"riseRate":0.4,"avgChangeRate":0.048055},{"month":7,"riseRate":0.7,"avgChangeRate":0.091843},{"month":8,"riseRate":0.545455,"avgChangeRate":0.006342},{"month":9,"riseRate":0.636364,"avgChangeRate":0.312097},{"month":10,"riseRate":0.363636,"avgChangeRate":0.031849},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.010369},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.071209}],"exchange":"NASDAQ","name":"Anixa Biosciences","nameEN":"Anixa Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Anixa Biosciences(ANIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Anixa Biosciences,ANIX,Anixa Biosciences股票,Anixa Biosciences股票老虎,Anixa Biosciences股票老虎国际,Anixa Biosciences行情,Anixa Biosciences股票行情,Anixa Biosciences股价,Anixa Biosciences股市,Anixa Biosciences股票价格,Anixa Biosciences股票交易,Anixa Biosciences股票购买,Anixa Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Anixa Biosciences(ANIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction